Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial-Reference-Cited by-同舟云学术

Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial

Published:2018-01-19 Issue:6 Volume:48 Page:411-423
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Suzuki Kazuyuki¹²,Endo Ryujin²,Takikawa Yasuhiro²,Moriyasu Fuminori³,Aoyagi Yutaka⁴,Moriwaki Hisataka⁵,Terai Shuji⁴⁶,Sakaida Isao⁶,Sakai Yoshiyuki⁷,Nishiguchi Shuhei⁷,Ishikawa Toru⁸,Takagi Hitoshi⁹,Naganuma Atsushi⁹^ORCID,Genda Takuya¹⁰,Ichida Takafumi¹⁰,Takaguchi Koichi¹¹,Miyazawa Katsuhiko¹²,Okita Kiwamu¹³

Affiliation:

1. Department of Nutritional Science; Morioka University; Iwate Japan

2. Division of Hepatology, Department of Internal Medicine; Iwate Medical University; Iwate Japan

3. Department of Gastroenterology and Hepatology; Tokyo Medical University; Tokyo Japan

4. Division of Gastroenterology and Hepatology; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan

5. Department of Medicine; Gifu University Graduate School of Medicine; Gifu Japan

6. Department of Gastroenterology and Hepatology; Yamaguchi University Graduate School of Medicine; Yamaguchi Japan

7. Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine; Hyogo College of Medicine; Nishinomiya Japan

8. Department of Gastroenterology; Saiseikai Niigata Daini Hospital; Niigata Japan

9. Department of Gastroenterology; National Hospital Organization Takasaki General Medical Center; Takasaki Japan

10. Department of Gastroenterology and Hepatology; Juntendo University Shizuoka Hospital; Shizuoka Japan

11. Department of Internal Medicine; Kagawa Prefectural Central Hospital; Takamatsu Japan

12. Clinical Development Department; ASKA Pharmaceutical Co., Ltd; Tokyo Japan

13. Shunan Memorial Hospital/Yamaguchi University; Yamaguchi Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.13045/fullpdf

Reference65 articles.

1. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification;Ferenci;Hepatology,2002

2. Pathogenesis, diagnosis, and treatment of hepatic encephalopathy;Atluri;J Clin Exp Hepatol,2011

3. Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement;Bajaj;Aliment Pharmacol Ther,2011

4. Prognostic significance of hepatic encephalopathy in patients with cirrhosis;Bustamante;J Hepatol,1999

5. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis;Arguedas;Dig Dis Sci,2003

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vitamin D deficiency stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis: A retrospective cohort study;Clinical Nutrition ESPEN;2024-10

2. Efficacy and Safety of Variable Treatment Options in the Prevention of Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis;Cureus;2024-01-31

3. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis;Cochrane Database of Systematic Reviews;2023-07-19

4. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy;Internal Medicine;2023-04-01

5. Effects of Rifaximin on Circulating Albumin Structures and Serum Ammonia Levels in Patients with Liver Cirrhosis: A Preliminary Study;Journal of Clinical Medicine;2022-12-09